Chairman Vivek Sharma steps down, Umang Vohra named new Group CEO

Ceo ResignedCeo Appointed ExternalKmp ResignedManagement Changes View source PDF Explain this filing

COHANCE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+20.4%Reaction day

₹358.95

prior close

₹380.35

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+1.8%+18.6% vs market

Pharmaceuticals peers, median of 163sector+0.9%+19.4% vs sector

On the reaction day the stock moved 18.6 pts more than Nifty Smallcap 250 and 19.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+12.3

10m

+11.6

15m

+11.4

30m

+13.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+20.4+1.8+18.6+0.9+19.4

Next day

+36.1+1.9+34.3+0.8+35.4

+30.9+2.4+28.5+0.3+30.6

+33.9+1.9+32.0+0.4+33.6

+30.1+2.9+27.2+0.8+29.3

+26.5+3.1+23.4+0.7+25.8

+35.4+6.1+29.3+3.2+32.1

15d

+19.0+1.5+17.4+2.4+16.6

+19.8+4.2+15.6+4.2+15.6

+25.4+7.3+18.0+4.9+20.4

+18.7+8.6+10.1+8.2+10.5

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 163Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Cohance Lifesciences announced major leadership changes. Executive Chairman Mr. Vivek Sharma will resign effective April 30, 2026, but will serve as Special Advisor for 9 months to aid transition. Mr. Umang Vohra has been appointed as Chairman (May 1) and Group CEO (May 20) for a 5-year term, subject to shareholder approval. Board also approved ESOP 2026 with 2.59 crore options (6.25% dilution), exercise price not less than Rs 325/share.

Likely market impact

Smooth leadership transition with 9-month advisor handover. New external CEO appointed. ESOP 2026 signals retention focus. Subject to shareholder approval.